NCT05894876

A Study of the Genetic Basis of Response to Growth Hormone Treatment in Children With Idiopathic Short Stature

A Study of the Genetic Determinants of Response to Growth Hormone Treatment in Children With Idiopathic Short Stature

• Status: Terminated
• Phase: —
• Study type: Observational
• Enrollment: 43 (actual)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: All
• Age: 3 Years – 11 Years
• Healthy volunteers: —

Summary

The study doctor will collect information from participants with Idiopathic Short Stature, who were treated with growth hormone for at least a year when they were children, before they reached puberty. The word "Idiopathic" refers to "unknown cause", and as such the study participants have/had short stature with no identifiable medical cause. The purpose of the study is to identify differences in the genetic characteristics of participants who responded well or poorly to growth hormone therapy. No medications or other treatments are provided to the participants by Novo Nordisk as part of this study. The study will last for up to 1 year. The participants will attend their usual doctor's appointments. If the participants are not usually visiting the clinic, they will need to do it only once as part of this study. If the participant agrees to take part in the study, they will be asked to read and sign the 'Agreement to take part form'.

Conditions

• Idiopathic Short Stature

Interventions

Type	Name	Description
OTHER	No treatment is given	No treatment is provided to the participants as part of this study.

Timeline

• Start date: 2024-04-29
• Primary completion: 2025-03-21
• Completion: 2025-03-21
• First posted: 2023-06-08
• Last updated: 2025-12-12

Locations

4 sites across 3 countries: United States, Brazil, Israel